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SECTION 1: INTRODUCTION
This document addresses procedures for the audiological surveillance of hearing of infants and young children at
risk for late onset or progressive permanent hearing loss (PHL). It is closely linked with the Ontario Infant Hearing
Program (IHP) Protocol for Universal Newborn Hearing Screening, Auditory Brainstem Response Assessment (ABRA)
Protocol, and the IHP protocol for Audiometric Assessment for Children Aged 6 to 60 Months with respect to risk
indicators, hearing screening technology applied, screening bypass, and audiological assessment procedures.
Infants are most often identified as having a risk indicator for late-onset or progressive PHL at the hearing
screening stage. The designation of risk at the hearing screening stage informs which hearing screening technology
(automated distortion product otoacoustic emission (ADPOAE) or automated auditory brainstem response (AABR))
is applied or whether hearing screening is bypassed and audiological assessment is initiated. If the infant passes
the hearing screening or the audiological assessment is within normal limits and the risk factor screen is negative,
and depending on the risk indicator, the infant may be discharged from the IHP or entered into a particular
surveillance sequence (Basic or Intensive). Most Surveillance sessions will consist of visual reinforcement
audiometry (VRA) and some early sessions will require an ABR assessment, both of which must be conducted by an
IHP Audiologist authorized in those IHP protocols. If during a Surveillance session the child is identified as having
PHL, the child will be offered the necessary intervention supports provided by the IHP as guided by current
protocols and guidelines (i.e., Provision of Amplification Protocol, Language Development Services Guidelines).
The scope of this document includes the details of the Surveillance procedures as funded by the Ministry of
Children, Community and Social Services (MCCSS) for the IHP.

1.1 VERSION HISTORY
This version of the IHP High-Risk Surveillance Protocol (2019.01) supersedes all previous documents relating to
high risk surveillance. It is substantially revised from previous documents related to Surveillance within the IHP.

VERSION DATE

DOCUMENT TITLE

PREVIOUS VERSION

2014

High Risk Surveillance Redesign:
Questions and Answers

2012 Memo

2012

Memo: Redesign of IHP High Risk
Surveillance

N/A

2008

N/A

Surveillance Implemented

Revisions to this version are largely due to changes to IHP Universal Newborn Hearing Screening (UNHS) which
now includes an additional risk factor screen using the dried blood spot (heel prick) sample collected by Newborn
Screening Ontario (NSO). Additionally, changes to the risk indicator list which drives the choice of hearing
screening technology, bypass of hearing screening, and Audiological Surveillance are included.

1.2 REVISION SUMMARY FOR VERSION 2019.01
Recent amendments to this Surveillance protocol are largely due to the introduction of the risk factor screen.

TOPIC
RISK FACTOR
SCREEN

DESCRIPTION

SECTION

With parent/guardian consent, NSO will
screen the dried blood spot from the
infant’s heel prick for congenital
cytomegalovirus (cCMV) and several

2.3
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genetic mutations associated with
permanent childhood hearing loss.
RISK INDICATORS

List of risk indicators has been updated.

3.2

GROUP 1 RISK
INDICATORS

Infants with these risk indicators who pass
their hearing screen will be discharged
from the IHP. There will be further
contact with the family if the infant
screens positive on the risk factor screen.

3.2.1

GROUP 2 RISK
INDICATORS

A single-point Basic Surveillance is
targeted at 15 to 18 months of age for
infants who have these risk indicators.

3.2.2

GROUP 3 RISK
INDICATORS

Hearing screening is bypassed and
surveillance will occur for infants with
these risk indicators with the rate of
recurrence dependent on the specific risk
indicator.

3.2.3

SURVEILLANCE
SEQUENCES

Due to the updated risk indicators,
surveillance sequences have been
modified and are determined by the
infant’s risk indicator.

3.6

SECTION 2: SCOPE
2.1 INFANT HEARING PROGRAM (IHP) CORE PRINCIPLES
Audiological Surveillance, using electrophysiological or behavioural measures as required, shall be provided in
accordance with the IHP core principles of informed parent/guardian choice and consent, timely provision of
unbiased information based on the best available scientific evidence, and sensitivity to family culture and values.
Further details about the IHP can be found in the IHP Guidance Document.

2.2 WHAT IS AUDIOLOGICAL SURVEILLANCE?
Audiological Surveillance is the proactive recall for an audiological assessment of young children who have been
identified within the IHP as having a risk indicator associated with late-onset or progressive PHL. Surveillance is
defined here to be Basic, which involves a single recall, or Intensive, involving a varying rate of recalls depending
on the risk indicator. Both sequences involve a complete audiological assessment that is developmentally
appropriate for the infant (e.g., auditory brainstem response assessment (ABRA), visual reinforcement audiometry
(VRA), conditioned play audiometry (CPA), standard audiometry).
In its broadest sense, Audiological Surveillance is a systematic process for the early detection of permanent
hearing loss (PHL) that is not detected by UNHS. There are a variety of reasons why PHL may not be detected by
UNHS. For instance, the child may not access UNHS through the IHP or the hearing loss was not present or
detectable at the time of the hearing screen.
Failure to detect hearing loss that is not yet present is not a false-negative screen. This situation is the major focus
of surveillance, as are hearing losses that are too small at the time of hearing screen and hearing losses that are
frequency-specific. Because surveillance is conducted using diagnostic hearing test technology and procedures

Page | 5

rather than screening technology and procedures, hearing losses that are present but undetectable by hearing
screening tests are detectable in those children who are selected for surveillance.

2.3 RISK FACTOR SCREEN
In 2013, the IHP undertook a collaborative project with Newborn Screening Ontario (NSO) and determined that it
was feasible for NSO to detect causes of PHL through blood spot screening including selected genetic mutations
and congenital cytomegalovirus (cCMV). The dried blood spot is already used to detect many other treatable
diseases and disorders in newborns. The addition of some genetic mutations known to cause PHL in infants as well
as cCMV, which is the leading environmental cause of PHL, will help ensure that follow-up occurs for infants who
pass UNHS and have a likelihood of late-onset or progressive PHL.
The goal of implementing the risk factor screen in newborns is to improve the program’s risk assessment process.
It will allow for earlier and more accurate identification of infants with specific risk indicators for PHL and their
subsequent assessment or surveillance monitoring.
Phase 1 was implemented in April 2018 and involved targeted cCMV screening for infants that had been referred
for audiology assessment following a refer on the hearing screening and where parent/guardian explicit informed
consent for the risk factor screen had been obtained.
Phase 2 was implemented in July 2019 and involves offering the risk factor screen universally. With
parent/guardian explicit informed consent, NSO will screen the dried blood spot for cCMV infection and several
common mutations on three genes that are known to cause PHL in infants and young children.

2.4 WHO CAN CONDUCT AUDIOLOGICAL SURVEILLANCE?
Only Audiologists registered with the College of Audiologists and Speech Language Pathologists of Ontario
(CASLPO) who are trained and authorized by the IHP to conduct this protocol AND at least one of the IHP
Assessment protocols (ABRA, Audiometric Assessment for Children Aged 6 to 60 months) may provide Audiological
Surveillance services with IHP funding. The assessment protocol for which an IHP Audiologist is authorized
indicates which surveillance strategy (e.g., ABR or behavioural) the Audiologist is authorized to conduct as part of
this protocol. The IHP Audiologist must personally conduct the testing and interpret the results. Students may also
participate with full supervision from the IHP Audiologist.
If an IHP Audiologist has been inactive in this or other IHP Assessment protocols for six months or more, the retraining review procedures in the IHP Guidance Document will apply.
Authorization for Surveillance may be withdrawn at the discretion of the MCCSS.

2.5 PROTOCOL ADHERENCE IS A REQUIREMENT
All IHP Surveillance must be conducted in adherence to this protocol as well as the IHP Assessment protocols; such
adherence is an expectation for continued authorization to provide IHP services. Sufficient documentation of
protocol adherence must be kept on file by the IHP Lead Agency/Audiologist to support clinical decision support
and/or standard practice reviews conducted by DTCs when necessary.

2.6 LEGITIMATE DEPARTURE FROM PROTOCOL
It is acknowledged that case-specific situations that justify departure from mandatory protocol elements can arise.
Such departures must be noted in the infant’s records with a brief explanation. All such notes must be accessible
for IHP standard practice review or case audits (see IHP Assessment protocols).
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2.7 PROCEDURAL CONCERNS
Prior approval by MCCSS is required in order to substantively change any element of this protocol. Program-wide
changes can occur only through MCCSS directive or by a systematic process that may include survey of
Audiologists’ experiences or concerns, evidence review, and recommendation by a Designated Training Centre
(DTC).
IHP Protocols are evidence-based to the extent possible. Evidence is reviewed by the DTCs on an ongoing basis.
This may result in specification of procedures that differ from opinions in published journals. Substantive issues
will be addressed by new evidence review, re-examination of existing evidence, and/or provincial consensus
development. Changes to IHP protocols are outside the mandate of regional IHP Lead Agency management and
shall be authorized ONLY by modification of the relevant IHP protocol document (such as this document), which
shall govern IHP Surveillance services throughout Ontario.

2.8 NON-IHP SERVICES
Hearing assessment services conducted by any person who is not an Audiologist authorized by the IHP shall not be
funded by the IHP and shall not be deemed to provide a sufficient basis for subsequent management within the
IHP. For this reason, and because of the prevalence of progressive hearing losses and/or conductive overlays in the
pediatric population, IHP Audiologists shall re-test a child prior to making inferences about hearing status and/or
candidacy for ongoing management.

2.9 POPULATIONS TARGETED
Candidates for surveillance include all Ontario-resident infants who have been identified, through the IHP UNHS
protocol, Risk Factor Screen, or referral into the IHP, as having at least one of the IHP risk indicators (see Appendix
B). Candidates must have:
1) Passed UNHS;
2) Bypassed UNHS and been found not to have PHL on audiology assessment ; or
3) Referred on UNHS and been found not to have PHL on audiology assessment.

Infants moving into Ontario or older siblings of infants with PHL identifed through the IHP must be assessed in the
community (i.e., not through the IHP). Referral into the IHP is warranted if the child is eligible (e.g., has PHL and is
younger than 6 years of age). Surveillance does not replace missed UNHS or retrospective audiology assessments
for siblings of newly-identified infants with PHL through the IHP.

2.10 TARGET DISORDERS
The IHP target disorder set includes PHL of > 30 dB HL at 0.5, 1, 2, or 4 kHz in any ear, auditory neuropathy
spectrum disorder (ANSD), and auditory brainstem pathway disorders that may be detectable using ABR
techniques (see IHP ABRA Protocol). The target PHL includes conductive impairment associated with structural
anomalies of the ear but does NOT include impairment attributable to minor, non-structural middle ear conditions.

2.11 CONDUCTIVE HEARING LOSS
The IHP is complementary to Ontario Health Insurance Plan (OHIP)-based, physician-driven audiology services and
does not replace them. Purely conductive hearing loss is not an IHP target unless obviously or presumptively
structural, such as in congenital atresia or if a syndrome associated with structural, conductive anomalies is
identified or suspected. For minor conductive losses, discharge from the IHP with caregiver counseling and
discretional referral to a physician is the norm. For more information, see the IHP Assessment protocols.
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2.12 OBJECTIVE OF AUDIOLOGICAL SURVEILLANCE
The main objectives of audiological surveillance are to:
1) Determine whether further audiological assessment is required; and
2) Potentially detect the presence of late onset or progressive PHL.
The overall surveillance goes beyond audiometry itself and includes family counseling and information about
follow-up.
It is widely acknowledged that, overall, audiological surveillance is a resource-intensive method of identifying
infants and young children at risk for PHL. The main reasons for this are that the majority of PHL associated with
current risk indicators identifiable perinatally is congenital, the positive predictive values (PPV) of most current risk
indicators for non-congenital PHL are very low, and the numbers of infants found to be at risk on some risk
indicators are very large. Furthermore, the PHL case yield from any given single-point surveillance depends upon
the distribution over age of the expression of the PHL (Boerst & Thorne, 2015).
Multi-point surveillance has also been applied and is resource intensive. The Joint Committee on Infant Hearing
(JCIH, 2000) revised their earlier surveillance recommendations to align with the impracticability of multiple
surveillance events. As such, multi-point surveillance will be applied when infants are identified as having a risk
indicator known to have a relatively high PPV and short PHL expression time-frames.
A measure of this resource expenditure per case identified is the number needed to test (NNT) to find one PHL
case in the group at risk on a given indicator and who did not refer on screening (Wood et al, 2013). For example,
how many babies who passed newborn hearing screening and had a wide Family History risk indicator were seen
for surveillance to identify one infant with PHL. In the 2.2 million babies analyzed retrospectively in the UK, the
NNT for this risk indicator was 909 (Wood et al, 2013). The range median was about 500 for the other risk
indicators. The corresponding median for babies who referred on screening was 4.9. This means that, overall,
surveillance is at best about 1% as effective at identifying PHL as assessment is in babies who refer on screening in
the UK sample.
Another issue to consider is the harm accrued from proactively visiting unproductive care upon families who did
not seek it. Such harms include anxiety and direct costs to large numbers of families for appointment attendance
that yield no benefit to them. It is about the balance of relatively small harms to the many against the relatively
large benefit for the few cases identified early and for whom intervention was effective. In surveillance, an option
is to limit it to those risk indicators with the lowest NNTs.
This protocol outlines the list of risk indicators used within the IHP and the surveillance sequence, if any, that must
be applied. Depending on the risk indicator, the infant may not be involved in surveillance or may participate in a
Basic or Intensive Surveillance sequence.

2.13 TARGET AGE RANGE
In practice, the overall target age range of children for potential surveillance within the IHP is from about three
months corrected age to about five years of age. It should be noted that corrected age is to be calculated using 37
weeks as full term (World Health Organization, 2018). Corrected age shall be calculated until the child turns two
years chronological age. Risk indicators associated with PHL expression only beyond five years are not included in
the IHP risk indicator list and the identification of PHL expressed beyond that limit is not within the purview of the
IHP. Specific age ranges for successful completion of ABR and behavioural assessment can be found in the
respective IHP Assessment protocols.
It is noteworthy when considering the target age for surveillance that the lower the age, the smaller the
proportion of infants with PHL already expressed. The others will likely be assessed as having normal hearing.
Alternatively, the higher the age, the larger the proportion expressed, but the older the infants are at PHL
identification.
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2.14 IHP DESIGNATED TRAINING CENTRES (DTC)
DTCs are authorized by the MCCSS to provide IHP support, including advanced training, consultative and
assessment referral services, IHP protocol support, and clinical decision support to IHP Audiologists and Regional
Trainers for various components of the IHP. DTCs also conduct standard IHP practice reviews and implement audits
of services as directed by MCCSS.
The DTCs for ABRA and conditioned behavioural audiometry (CBA) are CHEO (Ottawa) and Humber River Hospital
(HRH, Toronto). The National Centre for Audiology (NCA; Western University, London) is the DTC for Amplification,
Hearing Screening, and Surveillance.

2.15 IHP PROTOCOLS AND CASLPO GUIDELINES
Since surveillance includes ABR or behavioural assessment to be conducted by an Audiologist, the procedures shall
be practiced in full compliance with the requirements of both CASLPO and this protocol. IHP protocols may be
more specific than CASLPO guidelines. Effort is made to ensure that IHP protocols do not conflict with CASLPO
guidelines. Such conflicts may arise inadvertently and if any IHP Audiologist perceives such a conflict, the
Audiologist shall notify the DTC promptly and the IHP will act to resolve the issue.

2.16 INFECTION CONTROL STANDARDS
Infection control practices are typically governed by site-specific, institutional or agency protocols and are outside
the purview of this document. Generally accepted standards must be applied (CASLPO, 2010).

2.17 APPROVED TEST ENVIRONMENTS
Surveillance test areas must satisfy current ANSI standards for ABR or manual puretone audiometry (see IHP
Assessment protocols for details). If deviations from this cannot be avoided, they must be clearly documented. If a
refer on Surveillance is suspected in a test area that does not satisfy ANSI standards, it must be confirmed at a later
date in a test area that meets the standards.

2.18 CLINICAL RECORDS AND DATABASE REPOR TING
All audiometric records shall be maintained in a manner satisfying both CASLPO and the IHP. The records shall be
maintained in hardcopy or, if electronic medical records are used, in secure data files. For Surveillance conducted
using ABR, clinical records must include the test session listing of records that details the exact order of acquisition
of tracings. For Surveillance conducted using behavioural audiometry, clinical records must include details of the
procedure used to condition the child for VRA, the administration of control trials, the infant’s rate of correct
responses on control trials, and a worksheet showing the administration of VRA including control trial
administration. See IHP Assessment protocols for details. Records detailing interpretation of the Surveillance
session and reporting of any necessary information to Healthy Child Development – Integrated Services for
Children Information System (HCD-ISCIS) should also be available.

2.19 PERSONAL HEALTH INFORMATION
Management of all personal health information arising from the Surveillance process shall comply with local site
and legislative requirements and those of CASLPO. Information communicated for approved monitoring and
review procedures must be de-identified and code-referenced. All transmission of personally-identifiable
information shall be consented by the appropriate family member or authorized caregiver.
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SECTION 3: PROTOCOL FOR AUDIOLOGICAL SURVEILLANCE
3.1 RISK ASSESSMENT WITHIN THE IHP
A risk indicator is an identifiable characteristic of the child or medical procedure used with the child that is
associated with increased likelihood of PHL in that child greater than the likelihood in the newborn or child
population as a whole. Risk indicators are identified by the Hearing Screener through document review, consulting
nursing or medical staff, and talking to the family.
With respect to initial hearing screening in the community, if the Hearing Screener’s first contact with the family is
in a community facility, then the family/caregiver may be the only source of risk information other than the direct
physical observation of the Hearing Screener, such as for an obvious malformation of the external ear. A confident
and clear report of cleft palate by the family can be accepted. The remaining risk indicators require detailed
medical knowledge and if the family cannot confirm a risk indicator exists, then the infant should not be
considered At Risk. When in doubt, the decision should be No Risk and the default is ADPOAE screening. If a risk
indicator is present, hearing screening is done using AABR.
The purposes of risk assessment are to:
1) Determine whether hearing screening should be bypassed; or
2) Decide which hearing screening technology to use (i.e., ADPOAE or AABR); and
3) Record information that will determine whether the infant should receive later audiological testing
(surveillance) and, if so, what type of surveillance.
The complete list of IHP risk indicators is provided below and in Appendix B for quick reference. Information about
modifications from the previous list are described in the next sections.
The items on the list are the only IHP risk indicators that exist; no other medical conditions, treatments,
medications or family history items are acceptable. The only exception to this is a risk indicator specified by a
physician, which is itself an IHP risk indicator.
Note that an infant is not at risk unless and until at least one of the IHP risk indicators is determined to be present.
If no such determination is yet available, the infant is not at risk. There is no such thing as ‘probable risk’, it is
either present or it is considered not to be present.
It is the Hearing Screener’s responsibility to collect risk information, but it can be assisted by a nurse, except for
the Family History indicator, for which the Hearing Screener is responsible to ensure that the parent/guardian is
questioned exactly as specified in the IHP Hearing Screening Protocol. The role of a nurse is to assist with the
indicators related to specific medical conditions or procedures.
For infants who did not undergo a risk assessment by the Hearing Screener either in the hospital or the
community, it is the IHP Audiologist’s responsibility to conduct the risk assessment. It may be the case that the
infant is directed to Audiology following a positive result on the dried blood spot from the risk factor screen.

3.2 CURRENT IHP RISK INDICATORS
The list of IHP risk indicators has been modified based on preliminary evidence review, expert consultation, and
availability of IHP resources. In addition, the implementation of the risk factor screen has, in part, informed the
screening, bypass, and surveillance procedures. The list of IHP risk indicators and surveillance steps are found in
Appendix B. Table 1 represents the current risk indicators and surveillance sequences for the IHP.
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Table 1: Current IHP Risk Indicators and Surveillance Sequence
Group 1:
AABR Screen,
No Surveillance

Group 2:
AABR Screen,
Basic Surveillance if Pass

APGAR at 5 minutes ≤ 3

Cleft palate

Birthweight ≤ 1000g

Extracorporeal membrane
oxygenation (ECMO, ECLS)

Congenital Diaphragmatic Hernia
Family history of parent or sibling
with PHL identified by 10 years of
age

Hyperbilirubinemia meeting
exchange criterion, whether
exchanged or not

Hypoxic Ischemic Encephalopathy
(HIE) Sarnat II or III

Proven TORCHES infection
(toxoplasmosis, rubella, herpes
simplex virus, syphilis) except CMV

Intraventricular Hemorrhage (IVH)
Grade III or IV
Peri-ventricular Leukomalacia (PVL)

Group 3:
Bypass Screen, Refer to
Audiology, Basic or Intensive
Surveillance if Pass
Atresia/microtia (screen of
unaffected ear permitted)
CHARGE Syndrome
Proven Congenital
Cytomegalovirus (cCMV) including
cCMV screen positive on the dried
blood spot
Proven Meningitis
Genetic Screen Positive

Syndrome associated with PHL
except CHARGE

Persistent Pulmonary Hypertension
of the Newborn (PPHN)
Ventilatory support with at least
one of the following:
 High frequency ventilation
(HFJ, HFO, HFV)
 Inhaled nitric oxide (iNO,
NO)
Other risk identified by the
physician

3.2.1 GROUP 1 RISK INDICATORS
Infants who are identified as having a Group 1 risk indicator will undergo an AABR screening procedure. If the
hearing screening outcome is an overall ‘refer’ result, the infant is routed for an audiology assessment. If the
hearing screening outcome is an overall ‘pass’ result and the risk factor screen is negative, the infant does not
require audiological surveillance and is discharged from the IHP. The purpose of the Group 1 risk indicators is to
determine the type of hearing screening technology the Hearing Screener applies. The infant will be re-directed for
audiology assessment if the risk factor screen is positive following a ‘pass’ result on the hearing screening.

3.2.2 GROUP 2 RISK INDICATORS
Infants who are identified as having a Group 2 risk indicator will undergo an AABR screening procedure. If the
screening outcome is an overall ‘refer’ result, the infant is routed for an audiology assessment. If the screening
outcome is an overall ‘pass’ result, the infant enters into the Basic Audiological Surveillance sequence.
The exceptions for Group 2 are CHARGE and CMV. CHARGE is considered a syndrome known to be associated with
PHL. CMV is screened through the risk factor screen. Both are included as a separate risk indicator in Group 3 and
infants identified with either of these risk indicators bypass hearing screening.
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3.2.3 GROUP 3 RISK INDICATORS
Infants who are identified as having a Group 3 risk indicator will bypass hearing screening and go directly to an IHP
Audiologist for an ABR assessment. For certain risk indicators, like the ones in Group 3, the probability of PHL is
very high, so the possibility of false-negative screening is increased. In that case, the infant must be flagged for
routing directly to audiological assessment. Also, if the infant has atresia or microtia, it may be difficult or
impossible to obtain a satisfactory eartip insertion. In view of the likelihood of insertion failure as well as the high
PHL probability, the infant must be routed directly to Audiological Assessment.
If the infant is determined to have PHL following the assessment, supports and services within the IHP will be
offered including appropriate audiologic assessment follow-up which is not to be confused with surveillance.
Children with PHL do not by definition require surveillance. If the audiology assessment reveals normal hearing in
both ears, the infant enters into surveillance, which varies in frequency of appointments depending on the risk
indicator.

3.2.4 GENETIC MUTATION SCREEN POSITIVE FROM RISK FACTOR SCREEN
Infants who screen positive for one of the included genetic mutations and who pass an initial audiology
assessment will continue within the Intensive Surveillance sequence. This is because the likelihood of the infant
developing PHL is high and they should be closely monitored.

3.3 REVIEW OF UNCHANGED RISK INDICATORS
APGAR at 5 minutes ≤ 3: This traditional, multi-component indicator largely reflects cardio-pulmonary function and
has genuine, though limited, predictive relationships with long-term neurodevelopmental outcomes (Lieu, Ratnaraj
& Ead, 2013). It is retained due to its accessibility and to lack of evidence that the other, more specific indicators
here render it non-predictive.
Birthweight ≤ 1000g: This accessible, non-specific indicator defines the Extremely Low Birthweight (ELBW) group
(World Health Organization, 2004).
Congenital Diaphragmatic Hernia (CDH): If the diaphragm does not close completely, body structures normally
located below it can force their way up into the chest cavity, potentially compromising pulmonary and/or cardiac
function.
Hypoxic-Ischemic Encephalopathy (HIE): Moderate (Sarnat 2) or Severe (Sarnat 3): Encephalopathy is injury to brain
structures, in this case due to lack of oxygen, caused by either insufficient blood supply (ischemia) or to insufficient
oxygen-delivery capacity (hypoxemia), or both. Modified Sarnat is a severity scale.
Intraventricular Hemorrhage (IVH): Grade III or IV: The ventricles generate and circulate cerebrospinal fluid.
Especially in infants with low birth weight, the developing brain is vulnerable to deficient blood supply or oxygen
levels. Consequent cell injury or death can cause bleeding into the ventricular lining, the ventricular fluid space
itself or into nearby structures. Severity is graded I to IV, grades III and IV reflecting high risk of neurological and
neurodevelopmental sequelae, as well as concurrent cochlear damage.
Periventricular Leukomalacia (PVL): This is a brain injury characterized by coagulation or necrosis of nerve fibre
tracts (axons, white matter) near the lateral ventricles. It can affect the fetus or newborn; premature newborns are
at greater risk for this disorder.
Persistent Pulmonary Hypertension of the Newborn (PPHN): This indicator relates to compromise of the normal
post-partum circulatory transfer from the placenta to the lungs. It is a syndrome characterized by marked
pulmonary hypertension and resultant hypoxemia.
Ventilatory support with at least one of the following:
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Inhaled Nitric Oxide (iNO): Nitric oxide (NO) is a colorless gas with a sweet odour. It is a powerful vasodilator with a
strong relaxation effect on smooth musculature in the lungs, improving oxygenation. It may be used when
ventilation has insufficient effectiveness. It can decrease the need for use of major, invasive techniques such as
ECMO (see below).
High-Frequency Jet Ventilation (HFV, HFJ, HFJV), High-Frequency Oscillatory Ventilation (HFV, HFO, HFOV):
These are ventilation methods that deliver very small air volumes at very high repetition rates. It is used in a
variety of situations including acute respiratory failure, respiratory distress syndrome, and risk of lung injury from
conventional mechanical ventilation. It may serve as a ‘rescue’ when the conventional methods fail to achieve the
desired result.
Other risk indicator identified with confidence by a physician: Since the inception of the IHP, identification by a
physician of risk that is not specified in the remainder of the IHP indicator list has been a distinct indicator in itself.
It is impossible to list all conditions that incur valid risk of PHL. Even the indicators listed may be difficult or
impossible to discover by any other means and for some potential indicators, the complexity and contextspecificity of disorder expression makes it impossible to derive a simple, practicable risk indicator. It is not
intended that physicians adjust listed IHP indicators systematically, such as by declaring all unconfirmed meningitis
cases as at risk for example. However, in situations such as pending but unavailable confirmatory test results, it is
reasonable that if a physician judges the likelihood of risk confirmation in the individual case to be very high, then
proactive declaration of risk is preferable to completely missing the risk. This is especially important given that
HIV/measles/mumps have been deleted from the IHP risk indicator list (see below).
Extracorporeal Membrane Oxygenation (ECMO) or Extracorporeal Life Support (ECLS): An invasive life-support
technique in which blood is routed through an external gas exchange system for oxygenation and CO2 removal. In
neonates, it is used in situations of severe respiratory failure for which less drastic methods have not succeeded.
The duration of ECMO is typically 7-10 days, with the intent of life support during development or recovery of
improved lung function. ECMO is frequently used in cases of PPHN and CDH. It is not well-understood whether
ECMO itself or its indicating conditions (or both) are the main contributors to a high rate of PHL in ECMO survivors,
including late-onset PHL.

3.4 MODIFICATIONS TO CURRENT RISK INDICATORS
Based on preliminary evidence review, program data, and availability of IHP resources, some risk indicators have
been modified as follows:

3.4.1 FAMILY HISTORY
Family history of parent or sibling identified with PHL by 10 years of age: The main changes for this risk indicator is
that infants receive an AABR screen and are discharged from the IHP rather than entering into Surveillance. This
indicator is only useful if it is identified accurately, which can be a challenge if the appropriate information is not
gathered by the Hearing Screener. As such, it has a long history of false-positive identification which imposes a
significant strain on audiology assessment resources. A reduction in false-positive identification is expected with
the inclusion of a genetic panel within the risk factor screen. The genetic panel within the risk factor screen focuses
on selected common genetic mutations affecting three genes associated with significant and early PHL. These
account for some of the most common recessive mutations but is not an exhaustive screen of either all mutations
within the three genes, or all genes associated with pediatric PHL. In addition, the results of the risk factor screen
may not be known at the time of the hearing screen. Therefore, it is imperative for the Hearing Screener to
accurately identify a family history of hearing loss.
In the absence of the result of the risk factor screen, the family history risk indicator should be identified by the
Hearing Screener using a strictly-followed script for questioning of family members by IHP Hearing Screeners (see
IHP Screening Protocol). Only clear and definite affirmative responses should be accepted as placing the infant at
risk on this indicator. Note that half siblings who have PHL prior to age 10 years do not put the infant at risk.
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An infant with a family history of PHL will be screened using AABR. If the infant passes the hearing screening, s/he
will be discharged from the IHP and not included in a surveillance sequence. If the infant has a family history that is
related to an inherited syndrome associated with late-onset or progressive hearing loss, the infant could still be
eligible for surveillance when the syndrome is diagnosed by a physician.
Those infants who screen positive on the risk factor screen for genetics will be re-directed to audiology for
assessment regardless of any previous hearing screen outcome. Most of these children will be found to have
hearing loss at birth. For those where the audiology assessment indicates that there is no hearing loss at that time,
Intensive Surveillance will be scheduled.

3.4.2 OTHERS
Atresia/Microtia: The description for this risk indicator has changed from obvious craniofacial anomaly to
atresia/microtia. While there are many abnormal features of the head and neck that may be associated with PHL
risk, considerable expertise is required to identify them accurately. Also, the family may not be aware of the
abnormality, unless it has already been clearly identified medically as syndromic. Therefore, given that medical
records or medical/nursing staff may be consulted regarding syndromes, flagging of craniofacial malformations for
this risk indicator is restricted to abnormalities that are obvious to the layperson, in particular, atresia and
microtia. Atresia is identified with absent, closed, or slit-like external ear canal openings. Microtia includes absent
or grossly malformed ear(s). Atresia and microtia can have varying grades of severity.
CHARGE: The letters in CHARGE stand for: Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation
of Growth and development, and Ear abnormalities and deafness. Infants with CHARGE have a very high incidence
of PHL (~90%; e.g., Arndt et al, 2010; Blake et al, 1998; Holcomb et al, 2013). As well, these children usually have a
very complex audiological profile, with the possibility of sensorineural, both temporary and/or permanent
conductive, and ANSD components all present in the same child. As such, identification of this syndrome indicates
a screening bypass and referral directly to audiology for assessment.
Proven Congenital Cytomegalovirus (cCMV): Medical diagnosis of symptomatic cCMV infection external to the risk
factor screen may occur in hospital. This remains a part of the risk assessment completed by the Hearing Screener
and continues to be a bypass risk indicator. As described in the Risk Factor Screen section, cCMV can also be
screened with parental consent. As a result, infants who screen positive for cCMV who are not identified in
hospital will also have access to earlier identification and intervention, including possible treatment. Infants who
screen positive for cCMV on the risk factor screen will bypass any further hearing screening and go directly for an
audiology assessment. Many infants with cCMV will be asymptomatic (85-90%) with a 10% chance of developing
PHL in childhood (Fowler et al, 2017). Ten to 15% of infants will have signs or symptoms of cCMV identified at birth
such as rash, jaundice, or growth problems. Infants with symptomatic cCMV have a 30% chance of developing PHL
(Fowler et al, 2017), which supports the need for different surveillance sequence timing for the two groups
(Lanzieri et al, 2018).
Proven Meningitis: Meningitis is inflammation of the membranes (meninges) lining the brain and spinal cord. It is
an IHP risk indicator regardless of the specific pathogen involved (bacterial, viral, fungal, etc.), but only if the
presence of the pathogen is proven by a medical record or medical report. Family verbal report is not sufficient.
Neonatal meningitis is usually caused by vertical transmission during labor and delivery. It occurs most frequently
in the days following birth and is more common in premature infants. If meningitis is suspected, antibiotics are
typically initiated immediately and may eliminate the pathogen. If the pathogen’s presence has not been
confirmed, the infant is not at IHP risk on this indicator. Between 25 and 50 % of survivors will manifest some type
of morbidity in the first five years post-illness. Hearing loss is reported in about 25 % of cases (Bedford et al, 2001).
Wellman et al (2003) recommended ABRA in all cases at four to six weeks post-recovery.
Cleft palate: Cleft palate has a strong association with hearing loss, both permanent and temporary. Cleft lip alone
(isolated cleft lip) should, however, be used as a cue for search of any medical record or medical/nursing report
confirming presence of a cleft palate. Cleft lip was included in the previous list as a simple cue to possible cleft
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palate, but isolated cleft lip with no palatal cleft is common and not associated with PHL. Therefore, cleft lip is
hereby deleted as a risk indicator component.
Hyperbilirubinemia meeting exchange criterion, whether exchanged or not: Bilirubin levels that are hazardous
differ substantially according to the infant’s age and many other factors, including response to phototherapy. A
fixed concentration criterion (e.g., ≥ 400 µmol/L) does not reflect optimally the overall risk of neurological
sequelae. The modified wording reflects this clinical complexity. If an appropriate exchange criterion level is met,
intensive phototherapy may be sufficiently effective to avoid the need for actual exchange transfusion. It is
meeting an appropriate clinical criterion that constitutes the IHP risk indicator. Use of the term ‘kernicterus’ in a
medical record is in itself too variable and subjective to be a useful indicator component.
Other proven TORCHES infection: TORCH is the original acronym for the group of infections: Toxoplasmosis,
Rubella, CMV, Herpes Simplex Virus (HSV), and Other. Variations on the acronym have been tried and evolving
epidemiology has expanded the ‘Other’ group. For IHP risk indicator purposes, the only qualifying ‘Other’ infection
for this factor is Syphilis (organism: T.Pallidum), therefore TORCHES is used.
Syndrome associated with hearing loss in early childhood: About 50-60% of all hearing loss in childhood is genetic,
about one fifth of which is syndromic (Toriello et al, 2004). There are hundreds of genetically-based syndromes
associated with PHL in childhood. The vast majority are rare. Some of the more common, in approximate order of
decreasing prevalence at birth are: Down, Pendred/Enlarged Vestibular Aqueduct (EVA), Stickler, CHARGE, Usher,
Osteogenesis Imperfecta (OI), Goldenhar (OAVS), Waardenburg, Branchio-Oto-Renal (BOR)/Branchio-otic (BO),
Alport, Treacher-Collins, Neurofibromatosis II (NF2), and Crouzon. CHARGE is now an indicator on its own (see
above).

3.5 DELETED RISK INDICATORS
Based on preliminary evidence review, program data, and availability of IHP resources, the following risk indicators
have been deleted from Ontario’s list.
Gestation period ≤ 30 weeks: The 30 week criterion is too liberal. Gestational age estimates are inexact and
gestational period per se is now considered to add negligible predictive value to that of the other indicators listed.
Cleft lip: Cleft palate has a strong association with hearing loss, both permanent and impermanent, and remains on
the list (see above). Cleft lip was included in the previous list as a simple cue to possible cleft palate, but isolated
cleft lip with no palatal cleft is common and not associated with PHL. Cleft lip alone (isolated cleft lip) has been
removed and should, however, be used as a cue for search of any medical record or medical/nursing report
confirming presence of a cleft palate.
Congenital HIV, Measles or Mumps infection: Although these infections are reoccurring in the general population
due to the increase of non-vaccinated infants, the infections are often not proven at the time of the hearing
screening. As such, if an infection is proven beyond the hearing screening period (birth to two months of age), the
infant should be seen in the community for appropriate services.
Severe neonatal asphyxia/hypoxia/respiratory failure/cardiopulmonary failure: This indicator was intended to
increase the ease with which IHP Screeners could identify infants with hypoxia sufficient to cause serious risk of
cochlear injury. However, the terms are now recognized as too subjective and less predictive than the other
indicators included within the current list that relate to specific causes, sequelae or interventions associated with
severe hypoxia.
Severe neonatal sepsis: This indicator is now recognized to be neither sufficiently predictive of PHL nor specific.
The association with PHL is only established if the septicemia leads to proven meningitis, which is a separate risk
indicator on the current list.
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Neonatal cancer treatment with cisplatin: The issue of PHL caused by either maternal cancer chemotherapy during
pregnancy or, very rarely, cancer chemotherapy in the infant, is too complex and situation-specific to be addressed
by a simple risk indicator. Additionally, infants undergoing this treatment are included in an ototoxic monitoring
protocol which includes hearing.

3.6 SURVEILLANCE SEQUENCES AND RISK INDICATORS
Infants with no assigned IHP Risk Indicator for PHL will be screened using ADPOAE technology. About 95% of all
infants are not at risk for PHL. Initial likelihood of PHL is small and the number of infants large. This favours use of
an initial hearing screen using ADPOAE technology to quickly filter out all babies with the greatest probability of
having normal hearing at that time. The AABR screen takes more time, skill and expense, but is more resilient to
minor middle and outer ear dysfunction and will in turn eliminate many babies who are false-positive on ADPOAE.
Infants who have a risk indicator from Group 1 will be screened using AABR technology. If the infant passes the
hearing screen or is determined to have normal hearing at the audiology assessment, s/he will not enter into
surveillance. S/he will be discharged from the IHP if they are also determined to have a negative result on the risk
factor screen. Infants who are assigned an IHP risk indicator from Group 2 or 3 will enter into either Basic or
Intensive Surveillance, which are described in detail in the following sections (see Table 2). Infants with a Group 3
risk indicator will bypass screening and be routed directly for audiology assessment. If the infant is determined to
have normal hearing at the initial assessment, s/he is entered into either a Basic or Intensive Surveillance sequence
depending on the risk indicator. All surveillance appointments include a developmentally appropriate audiology
assessment. A quick guide for the clinical application of the surveillance sequences for each IHP risk indicator can
be found in Appendix C.
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Table 2: Summary of risk indicator groups and surveillance sequences.
Risk
Indicator
Group 1
Group 2

Action

Surveillance Classification

Surveillance Sequence

AABR Screen
Discharge if Pass

None

N/A

AABR Screen
Surveillance if Pass

Basic Sequence

15 to 18 months corrected
age

Bypass Hearing Screen
Refer for Audiology Assessment
If hearing within normal limits,
enter Surveillance.

Group 3

Basic Sequence:
Atresia/Microtia
CHARGE Syndrome

15 to 18 months corrected
age

Intensive Sequence:
Proven Meningitis
Proven cCMV: Asymptomatic*
Proven cCMV: Symptomatic*
Genetic Screen Positive

Proven Meningitis
3 assessments at 3 month
intervals
Proven cCMV:
Asymptomatic
10 to 12 months, 15 to 18
months, 3 years, 5 years
Proven cCMV:
Symptomatic
3 assessments at 3 month
intervals, 15 to 18 months,
3 years, 5 years

Genetic Screen Positive:
3 assessments at 3 month
intervals, 15 to 18 months,
3 years
*Note: Audiologists should categorize infants with proven cCMV as asymptomatic unless otherwise notified.

3.6.1 BASIC SURVEILLANCE
Basic Surveillance is likely to be optimal if done between one and two years of age. This corresponds to the JCIH
(2007) recommendations, among others (e.g., Sutton et al, 2012; Vos et al, 2015). It reflects the limited interest
shown by families in attending assessments after too-lengthy periods of apparently normal hearing in their infants.
Wood et al (2013) reported that only 55% of all families offered such appointments attended them. The resources
expended in tracking and contacting all such families to no avail are not to be underestimated. It also takes
account of the window of practicality for VRA in the target population.
Infants identified as having a risk indicator from Group 2 and atresia/microtia and CHARGE syndrome from Group 3
and who pass their hearing screen or audiological assessment will enter into Basic Surveillance. This single-point
activity is targeted to occur between 15 to 18 months corrected age. Earlier than about 15 months limits the
amount of PHL likely to be expressed. Later than about 18 months of age limits the likelihood of successful and
efficient VRA, while play audiometry is still unlikely to be widely effective.
The Basic Surveillance appointment will consist of a complete audiological assessment as described in the IHP
Audiometric Assessment for Children Aged 6 to 60 months protocol. Briefly, in each ear, VRA shall be conducted via
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air conduction at 500, 2000, and 4000 Hz. Case history, otoscopy, immittance, and DPOAEs shall also be obtained
and the results interpreted accordingly to satisfy the cross-check principle (Norrix, 2015).
Priority is given to obtaining VRA results with recommended cross-check from DPOAEs. If the result on Basic
Surveillance is a pass in both ears, then the child shall be discharged from the IHP. No further surveillance
appointments are required. If the child is identified as having PHL during the surveillance appointment, next step
IHP supports and services shall be offered and no further surveillance is required.

3.6.2 INTENSIVE SURVEILLANCE
Infants identified as having a risk indicator from Group 3 (except atresia/microtia and CHARGE syndrome) and who
pass their audiological assessment will enter into Intensive Surveillance. This surveillance sequence is multi-point
and varies depending on the risk indicator. Regardless of the number of surveillance appointments, all infants with
the relevant risk indicator from Group 3 will undergo a complete audiology assessment that is developmentally
appropriate. That is, for infants under six months corrected age, an ABR assessment must be conducted and
conditioned behavioural assessment must be conducted in infants six months and older, as developmentally
appropriate. For either strategy, the current IHP Assessment Protocols apply (e.g., ABR Assessment and
Audiometric Assessment for Children aged 6 to 60 months).
The risk-dependent Intensive Surveillance sequences are as follows:
1) Proven Meningitis: 3 assessments at 3 month intervals from the time of the first normal assessment
2) Proven cCMV with no symptoms (asymptomatic)*: 10 to 12 months, 15 to 18 months, 3 years, and 5 years
3) Proven cCMV with symptom(s) (symptomatic)*: 3 assessments at 3 month intervals from the time of the
first normal assessment, then 15 to 18 months, again at 3 years and 5 years
4) Genetic screen positive: 3 assessments at 3 month intervals from the time of the first normal assessment,
then 15 to 18 months and again at 3 years
* Audiologists should categorize infants with proven cCMV through the risk factor screen as asymptomatic unless
otherwise notified.
If normal hearing in both ears is confirmed during an Intensive Surveillance appointment within the sequence or a
clinical decision is made that PHL is unlikely, the child shall be booked for the next surveillance appointment. If
normal hearing in both ears is confirmed at the final appointment of the sequence, the child shall be discharged
from the IHP. No further surveillance appointments are required. If the infant is identified as having PHL during any
Intensive Surveillance appointment, next step IHP supports and services shall be offered and no further
surveillance is required. For infants with proven meningitis who are identified as having PHL, the IHP Audiologist’s
prompt referral to a cochlear implant program is recommended due to the possibility of ossification of the cochlea.
Infants with incomplete or inconclusive results during the Intensive Surveillance appointment shall be rebooked for
the next appointment within the sequence.

3.7 NUMBER OF SURVEILLANCE ATTEMPTS
Every effort should be made to complete the surveillance apointment in as few visits as possible. This should
include parent counselling on how to prepare the child for the next visit and activities that can be done at home to
help train the child to be better prepared to condition for the testing at the next visit (e.g., working on sound
awareness). Review the relevant sections of the IHP Assessment protocols for helpful strategies for ABR and
behavioural audiometry.
Infants who have incomplete or inconclusive results during a surveillance appointment should be rebooked no
more than two times for a total of three attempts. These appointments should be closely scheduled and occur
within a three month time period if part of the Basic Surveillance sequence. For Intensive Surveillance, the child
should be moved to the next scheduled surveillance visit.
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If a complete assessment has not been achieved after the third attempt, the Audiologist must be prepared to make
a clinical decision based on any information that was obtained. This may include ear-specific or soundfield
responses, tympanometry, DPOAEs, acoustic reflexes, progress in listening skills, and parent reports on
responsiveness to sound, which may include the LittlEARS auditory questionnaire (see IHP Provision of
Amplification Protocol). If there is no information to indicate that PHL has developed, the child should either be
moved to the next scheduled surveillance visit if the risk indicator requires Intensive Surveillance, or be discharged
from the IHP with appropriate counselling to the family regarding monitoring the child’s responsiveness to sound,
and clear documentation of the rational for the decision. If the family has future concerns about their child’s
hearing, they should arrange for a hearing assessment in the community (i.e., not through IHP).
If there is concern that a PHL may be present based on the information that was obtained, consideration of a
natural sleep ABR or sedated ABR referral may be warranted. If the audiologist is unable to come to a clinical
decision, consultation with the DTC for clinical decision support must occur.

Page | 19

APPENDICES
APPENDIX A: REFERENCES
Arndt S, Laszig R, Beck R, Schild C, Maier W, Birkenhager R, Kroeger S, Wesar T, Aschendorff A (2010). Spectrum of
hearing disorders and their management in children with CHARGE syndrome, Otology & Neurology, 31(1),
67-73.
Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D (2001). Meningitis in infancy in England and
Wales: follow up at age 5 years, British Medical Journal, 323, 533-536.
Blake K, Davenport S, Hall B, Hefner M, Pagon R, Williams M, Lin A, Graham J (1998). CHARGE association: an
update and review for the primary pediatrician, Clinical Pediatrics, 37(3), 159-173.
Boerst A, Thorne M (2015). Age of identification of delayed onset hearing loss in infants and young children,
Retrieved from
https://www.infanthearing.org/meeting/ehdi2010/ehdi_2010_presentations/Age%20of%20Identification
%20of%20Delayed%20Onset.pdf on July 5, 2019.
College of Audiologists and Speech-Language Pathologists of Ontario (2016). Practice Standards for the Provision of
Hearing Aid Services by Audiologists. Retrieved from:
http://www.caslpo.com/sites/default/uploads/files/PS_EN_Practice_Standards_for_the_Provision_of_He
aring_Aid_Services_By_Audiologists.pdf on July 16, 2019.
Fowler K, McCollister F, Sabo D, Shoup A, Owen K, Woodruff J, Cox E, Mohamed L, Choo D, Boppana S (2017). A
targeted approach for congenital cytomegalovirus screening within newborn hearing screening,
Pediatrics, 139(2), 1-8.
Holcomb M, Rumboldt Z, White D (2013). Cochlear nerve deficiency in children with CHARGE syndrome,
Laryngoscope, 123(3), 793-796.
Joint Committee on Infant Hearing (JCIH) (2000). Year 2007 position statement: Principles and guidelines for early
hearing detection and intervention programmes, Pediatrics, 106(4), 798–817.
Joint Committee on Infant Hearing (JCIH) (2007). Year 2007 position statement: Principles and guidelines for early
hearing detection and intervention programmes, Pediatrics, 120(4), 898–921.
Lanzieri T, Chung W, Leung J, Caviness C, Baumgardner J, Blum P, Bialek S, Grosse S, Demmler-Harrison G,
Congenital Cytomegalovirus Study Group (2018). Hearing trajectory in children with congenital
cytomegalovirus infection, Otolaryngology Head and Neck Surgery, 158(4), 736-744.
Lieu JE, Ratnaraj F, Ead B (2013). Evaluating a prediction model for infant hearing loss, Laryngoscope, 120(11),
2873-2879.
Norrix, L (2015). Hearing Thresholds, Minimum Response Levels, and Cross-Check Measures in Pediatric Audiology.
American Journal of Audiology, 24, 137-144.
Sutton G, Wood S, Feirn R, Minchom S, Parker G, Sirimanna T (2012). Guidelines for surveillance and audiological
referral of infants and children following the newborn hearing screen: Version 5, Newborn Hearing
Screening Programme, UK. Retrieved from
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/494
611/NHSP_Surveillance_guidelines_v5-1_290612.pdf on July 17, 2019.
Page | 20

Toriello HV, Reardon W, Gorlin RJ, eds. (2004) Hereditary Hearing Loss and Its Syndromes, New York: Oxford
University Press.
Wellman M, Sommer D, McKenna J (2003). Sensorineural hearing loss in postmeningitic children Otology and
Neurotology, 24(6), 907-912.
Wood SA, Davis A, Sutton G (2013). Effectiveness of targeted surveillance to identify moderate to profound
permanent childhood hearing impairment in babies with risk factors who pass newborn screening,
International Journal of Audiology, 52, 394-399.
World Health Organization: International statistical classification of disease and related health problems (2004).
Tenth
Revision, 2nd Ed. (ICD-10), Geneva: World Health Organization; 2004.
World Health Organization Fact Sheet: Preterm Birth (2018). Geneva: World Health Organization, Retreived from
https://www.who.int/news-room/fact-sheets/detail/preterm-birth on July 26, 2019.
Vos B, Senterre C, Lagasse R, SurdiSCreen Group, Leveque, A (2015). Newborn hearing screening programme in
Belgium: a consensus recommendation on risk factors, BioMed Central Pediatrics, 15, 1-14.

Page | 21

APPENDIX B: IHP RISK INDICATORS FOR PERMANENT HEARING LOSS
Risk Indicator
Group 1
Apgar ≤ 3 at 5 minutes
Birthweight ≤ 1000 g
Congenital Diaphragmatic Hernia
Family history <10 yrs of age parent or sibling
Hypoxic Ischemic Encephalopathy (Sarnat II or III)
Intraventricular Hemorrhage (Grade III or IV)
Peri-ventricular Leukomalacia
Persistent Pulmonary Hypertension of the Newborn
Ventilatory support: iNO/NO, HFJ/HFO/HFV
Other risk identified by physician
Group 2
Cleft Palate
Extracorporeal Membrane Oxygenation (ECMO)
Hyperbilirubinemia (exchange levels)
Other proven TORCHES infection
Syndrome associated with childhood PHL (not CHARGE)
Group 3
Atresia/Microtia
CHARGE Syndrome
Proven Meningitis
Proven Congenital Cytomegalovirus: Asymptomatic
Proven Congenital Cytomegalovirus: Symptomatic
Genetic Screen Positive

Screen Bypass

Basic
Surveillance

Intensive
Surveillance

No
No
No
No
No
No
No
No
No
No

No
No
No
No
No
No
No
No
No
No

No
No
No
No
No
No
No
No
No
No

No
No
No
No
No

Yes
Yes
Yes
Yes
Yes

No
No
No
No
No

Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
No
No
No
No

No
No
Yes
Yes
Yes
Yes
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APPENDIX C: QUICK GUIDE FOR CLINICAL APPLICATION OF SURVEILLANCE SEQUENCES

Risk Indicator
Group 1
Apgar ≤ 3 at 5 minutes
Birthweight ≤ 1000 g
Congenital Diaphragmatic Hernia
Family history <10 yrs of age
parent or sibling
Hypoxic Ischemic Encephalopathy
(Sarnat II or III)
Intraventricular Hemorrhage
(Grade III or IV)
Peri-ventricular Leukomalacia
Persistent Pulmonary
Hypertension of the Newborn
Ventilatory support: iNO/NO,
HFJ/HFO/HFV
Other risk identified by physician
Group 2
Cleft Palate
ECMO
Hyperbilirubinemia (exchange
levels)
Proven TORCHES infection
Syndrome associated with
childhood PHL (not CHARGE)
Group 3
Atresia/Microtia
CHARGE Syndrome
Proven Meningitis
Proven cCMV: Asymptomatic
Proven cCMV: Symptomatic
Genetic Screen Positive

3 ax at 3
month
intervals

10 – 12
months

15 – 18
months

3 years

5 years
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